Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Novel Coronavirus COVID-19 Research Guide: Therapeutics

Library resources, news, and other trusted resources for health care providers and public health professionals about COVID-19.

Introduction and News

This page is designed to include guidelines, consensus statements, overview articles, and current systematic reviews and meta-analyses on therapies for Covid 19.  Recent reports from major scholarly publications are included and there are links to data sets, disease trackers, and major clinical trial sites.

 

Column 1 Navigation

Antivirals

Monoclonal Antibodies

Protease Inhibitors

Anti-coagulation

RAAS Inhibitors

Data on Variants

Anti-virals

Remdesivir

Other Antivirals

Monoclonal Antibodies

Protease Inhibitors

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5:S0140-6736(20)32013-4. doi: 10.1016/S0140-6736(20)32013-4. Epub ahead of print. PMID: 33031764; PMCID: PMC7535623.

Anti-coagulation

RAAS Inhibitors

JAK Inhibitors

  • Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, Kalil Filho R, Junior VM, Soeiro AM, Tognon AP, Veiga VC, Martins PA, Moia DDF, Sampaio BS, Assis SRL, Soares RVP, Piano LPA, et al; STOP-COVID Trial Investigators. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jun 16:NEJMoa2101643. doi: 10.1056/NEJMoa2101643. Epub ahead of print. PMID: 34133856; PMCID: PMC8220898.

Data on Variants

Column 2 Navigation

Trackers

Recommendations

Immunosuppressants

Anti-Inflammatory Approaches

Immunoglobulins

Other therapeutics

Trackers

Recommendations/Guidelines

Immunosuppressants

Mariette X, et al "Effectiveness of tocilizumab in patients hospitalized with COVID-19: A follow-up of the CORIMUNO-TOCI-1 randomized clinical trial" JAMA Intern Med 2021; DOI: 10.1001/jamainternmed.2021.2209.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.

Lin WT, Hung SH, Lai CC, et al. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Mar 24;96:107602. doi: 10.1016/j.intimp.2021.107602.

Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021 Mar 4. pii: S2213-2600(21)00081-3. doi: 10.1016/S2213-2600(21)00081-3.

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Ivan O. Rosas, M.D., Norbert Bräu, M.D., Michael Waters, M.D., Ronaldo C. Go, M.D., Bradley D. et al ,
February 25, 2021
DOI: 10.1056/NEJMoa2028700 NEJM

Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.

Anti-Inflammatory Approaches

Immunoglobulins

Other Therapeutics

Column 3 Navigation

Resources for Conducting Research/CDC Resources

Interferons

Antihelmintics

Vitamins

Antibiotics

Not Recommended Therpaies

Resources for Conducting Research/CDC Resources

Interferons

Anti-helmintics

Vitamins

Antibiotics

Not Recommended Therapies

Hydroxychloroquine

Convalelscent Plasma

The Himmelfarb Health Sciences Library
Questions? Ask us.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The George Washington University